CymaBay Therapeutics Inc (NASDAQ:CBAY) – Investment analysts at Oppenheimer decreased their FY2019 EPS estimates for CymaBay Therapeutics in a research note issued to investors on Tuesday, November 5th. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will earn ($1.48) per share for the year, down from their prior estimate of ($1.44). Oppenheimer also issued estimates for CymaBay Therapeutics’ Q4 2019 earnings at ($0.38) EPS, FY2021 earnings at ($1.36) EPS, FY2022 earnings at ($0.70) EPS and FY2023 earnings at $0.42 EPS.
A number of other brokerages have also commented on CBAY. BidaskClub upgraded CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 23rd. HC Wainwright reiterated a “buy” rating on shares of CymaBay Therapeutics in a research report on Wednesday. ValuEngine upgraded CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday. Cantor Fitzgerald set a $20.00 price objective on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Zacks Investment Research upgraded CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Tuesday, October 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $13.25.
CBAY stock traded up $0.34 during midday trading on Friday, reaching $5.93. 997,105 shares of the company’s stock traded hands, compared to its average volume of 865,411. The company has a 50-day simple moving average of $4.98 and a two-hundred day simple moving average of $7.53. CymaBay Therapeutics has a 1-year low of $4.23 and a 1-year high of $14.00. The company has a market cap of $356.56 million, a price-to-earnings ratio of -4.71 and a beta of 1.25. The company has a quick ratio of 16.20, a current ratio of 16.20 and a debt-to-equity ratio of 0.01.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01).
In other CymaBay Therapeutics news, CEO Sujal Shah purchased 5,000 shares of CymaBay Therapeutics stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the acquisition, the chief executive officer now owns 111,900 shares of the company’s stock, valued at approximately $618,807. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 11,900 shares of company stock valued at $59,600 in the last quarter. 4.20% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of CBAY. Quantitative Systematic Strategies LLC bought a new position in CymaBay Therapeutics during the second quarter worth about $252,000. Bailard Inc. grew its stake in shares of CymaBay Therapeutics by 43.5% in the second quarter. Bailard Inc. now owns 308,700 shares of the biopharmaceutical company’s stock worth $2,210,000 after purchasing an additional 93,600 shares during the last quarter. Aperio Group LLC bought a new stake in shares of CymaBay Therapeutics in the second quarter worth $104,000. Swiss National Bank grew its stake in shares of CymaBay Therapeutics by 2.1% in the second quarter. Swiss National Bank now owns 112,900 shares of the biopharmaceutical company’s stock worth $808,000 after purchasing an additional 2,300 shares during the last quarter. Finally, National Asset Management Inc. bought a new stake in shares of CymaBay Therapeutics in the second quarter worth $165,000. Institutional investors and hedge funds own 98.81% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Story: What is the price-sales ratio?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.